Key Highlights

● ClearPoint Neuro shares plunged on Tuesday, September 29, 2026, with a similar slide already visible in premarket trading.

● ClearPoint had no negative news of its own, and the selling reflected its role delivering uniQure's therapy into the brain.

● ClearPoint makes an MRI-guided platform that helps neurosurgeons place devices and inject therapies into targeted areas of the brain.

● uniQure's four-year AMT-130 data failed to reach statistical significance on a primary clinical measure, so ClearPoint fell in sympathy.

ClearPoint Neuro, Inc. (NASDAQ:CLPT) plunged on Tuesday, September 29, 2026, caught in the fallout from uniQure's disappointing four-year data for its Huntington's disease gene therapy, AMT-130. Market reports showed a steep drop in ClearPoint's shares, and a similar slide was flagged in premarket trading. ClearPoint had no negative news of its own.

The Link Between the Two Companies

ClearPoint makes a navigation and delivery platform that helps neurosurgeons place devices and inject therapies precisely into targeted areas of the brain, typically guided by MRI imaging. As more gene and cell therapies aim at brain diseases, precision delivery has become an important piece of the development puzzle. uniQure's AMT-130 is administered using ClearPoint's platform, which ties ClearPoint's growth prospects, at least in part, to the success of therapies like it. If a high-profile therapy delivered through the platform stumbles, investors may worry about future demand.

What Went Wrong at uniQure

uniQure released 48-month data from its Phase I/II study. One summary said the treatment failed to achieve statistical significance on a primary clinical measure at 48 months despite showing dose-dependent slowing of disease progression. The slowing in the high-dose group was smaller than at three years, and more than half of the external-control data was missing. uniQure's stock collapsed.

uniQure Defends the Results

Chief Executive Matt Kapusta said the trends are positive and meaningful for patients, and argued that the comparison group's makeup worked against the therapy. The FDA had said 36-month data would underpin the Biologics license application.

A Soft Day for Health Care

ClearPoint's decline fit into a weak session for health care, which was among the declining sectors at midday. The Russell 2000 finished lower, with closing figures from different sources clustered between roughly 2,807 and 2,810. The 30-year Treasury Yield reached its highest level since 2002, and the 10-year touched its highest in roughly two decades.

Watchlist Items

The path of uniQure's regulatory filing for AMT-130 is the most direct link, since progress there would bear on Demand for the platform. Investors may also look for commentary from ClearPoint on its broader base of biopharma partners and procedures. GDP and August PCE Inflation arrive on Wednesday, September 30, Nike reports on Thursday, October 1, and the September jobs report follows on Friday, October 2.